JIPOAd
ESID
TCR
  • Users Online: 112
  • Print this page
  • Email this page
CASE REPORT
Year : 2020  |  Volume : 3  |  Issue : 1  |  Page : 27-30

Pneumocystis infection in two patients treated with both immune checkpoint inhibitor and corticoids


1 Department of Medical Oncology, Institut Jules Bordet, ULB, Brussels, Belgium
2 Department of Internal Medicine, Institut Jules Bordet, ULB, Brussels, Belgium
3 Department of Microbiology, University Laboratory LHUB-ULB, Brussels, Belgium
4 Department of Anatomopathology, Institut Jules Bordet, ULB, Brussels, Belgium
5 Department of Dermatology; Department of Medical Oncology, Erasme Hospital, ULB; Department of Medical Oncology, UZ Brussel,VUB, Brussels, Belgium

Correspondence Address:
Dr. Sandrine Aspeslagh
Department of Medical Oncology, UZ Brussel, VUB, Laarbeeklaan 101, 1090 Brussels
Belgium
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JIPO.JIPO_23_19

Get Permissions

The introduction of immune checkpoint inhibitor (ICI) targeting cytotoxic T-lymphocyte-associated antigen-4 and programmed cell death receptor 1 has dramatically improved clinical outcome for cancer patients. Nevertheless, this treatment can be associated with immune-related adverse events (irAEs) which sometimes need management with prolonged immune suppression. In order to analyze the risk of Pneumocystis jiroveci pneumonia (PJP) in this population, all PJP cases at our oncological hospital between 2004 and 2019 were searched. Only two cases were found in patients treated with ICI (480 patients received ICI during that period). The first was treated with both ipilimumab and nivolumab for metastatic melanoma and required long-term corticosteroids plus infliximab for immune-related colitis. The second received both pembrolizumab and brentuximab for Hodgkin's lymphoma and received corticosteroids for macrophage-activating syndrome. These two cases illustrate that PJP is rare but might be severe in the ICI population and should be differentiated from tumor progression or irAE.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed375    
    Printed18    
    Emailed0    
    PDF Downloaded44    
    Comments [Add]    

Recommend this journal